Background There have been reports of serious side effects of Remdesivir,
including cardiovascular complications. The present study aimed to determine the
adverse cardiovascular effects of Remdesivir and the factors affecting them in
COVID-19 patients.
Methods The patients were classified into two groups: those receiving
Remdesivir without cardiac complications and those receiving Remdesivir with
cardiovascular complications. After reviewing the patientʼs medical records, the
relationship of some factors with the incidence of adverse cardiovascular
effects was measured.
Results Chi-square test showed that the distribution of complications in
men was significantly higher than in women (P=0.001). The independent t-test
revealed that the mean age in the group with complications was significantly
higher than the group without complications (P=0.013). Fisherʼs exact test
demonstrated a significant relationship between smoking and cardiovascular
complications (P=0.05). According to the Mann-Whitney test, a significant
difference was found in the mean changes of Bilirubin (P=0.02) and ALKP (P=0.01)
before and after treatment in the groups with and without heart
complications.
Conclusion Our findings indicated that most of the COVID-19 patients
suffered from sinus bradycardia, and the distribution of complications was more
pronounced in men than in women. The mean age in the group with complications
was higher than the group without complications. Smoking was found to be
associated with the occurrence of cardiovascular complications and the mean
changes of Bilirubin and ALKP before and after treatment were significantly
different in the groups with and without cardiovascular complications.